ClinicalTrials.gg
Active, not recruitingNCT06682910Microtech-LVADUpdated Aug 21, 2026

Assessment of Safety and Accuracy of the Microtech System in Patients Undergoing Left Ventricular Assist Device Implantation

An interventional study of Microtech sensor pressure in Heart Failure, sponsored by Microtech Medical Technologies, Ltd. Active, not recruiting at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Microtech Medical Technologies, Ltd · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
1,291st of 1,602
15 · median 66
Started
2024
with 108 others
No phase
887 of 2,159
159 open now
Primary completion
2026-11
later than 117 of 438 live
Registered
1,962nd of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 1,291st largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 109 that started in 2024, is one of 887 with no phase, reaches primary completion later than 117 of the 438 other live ones, and was the 1,962nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The Microtech-LVAD study is designed as a prospective, single arm, multi-center early feasibility study. Approximately 15 patients will be enrolled in the study. The study will be limited to patients in whom it is decided, based on routine clinical practice, that the LVAD will be implanted via a midline sternotomy. In the first 5 study patients, the device will be implanted in the RA; subsequently, the device will be implanted in the LA unless the patient is deemed at high risk of post-LVAD right heart failure, in which case the device will be placed in the RA

Read the detailed description

The Microtech-LVAD study is designed as a prospective, single arm, multi-center early feasibility study. Approximately 15 patients will be enrolled in the study. The study will be limited to patients in whom it is decided, based on routine clinical practice, that the LVAD will be implanted via a midline sternotomy. In the first 5 study patients, the device will be implanted in the RA; subsequently, the device will be implanted in the LA unless the patient is deemed at high risk of post-LVAD right heart failure, in which case the device will be placed in the RA. Clinical data will be collected pre-operatively, intra-operatively, throughout the post-operative hospitalization period, at discharge and at 1, 3-6, 9 and 12 months post-index procedure

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is scheduled to undergo an elective LVAD implantation via midline sternotomy based on routine practice at the participating center.
  • Patient is characterized as INTERMACS profile 2 or greater.
  • Patient is able and willing to provide written .
  • Patient is willing and able to comply with all required post-procedure follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Pre-operative coagulopathy or thrombocytopenia
  • For an intended LA implant, patient has a device implanted in the left atrial appendage (e.g., WATCHMAN or similar device) or a mechanical mitral valve
  • Patient has an atrial myxoma
  • Patient has pre-operative evidence of thrombus in the chamber in which the device is intended to be implanted
  • Patient has a history of stroke or within 6 months prior to the index procedure
  • History of systemic or pulmonary thromboembolism or deep vein thrombosis (DVT) within the last 6 months
  • Patient has a history of congenital heart disease, including known atrial septal defect that is not corrected (including during the LVAD implantation procedure)
  • Patient has severe mitral regurgitation (for an LA implant) or severe tricuspid regurgitation (for an RA implant) that is not intended to be corrected during the LVAD implantation
  • Patient has known allergy to stainless steel or titanium
  • Patient has noncardiac comorbidity that, in the opinion of the Principal Investigator, may limit to less than 1 year
  • Patient is pregnant or intends to become pregnant prior to completion of all protocol follow-up requirements
  • Patient is participating in another study that has not reached its primary endpoint
  • Intraoperative identification of any anatomical finding that would preclude safe access to, or closure of, the intended atrial chamber, or fixation of the device within the chamber including, but not limited to:

    1. Identification of thrombus in the atrium in which the device will be implanted
    2. Atrial anatomy deemed to be too thin or fragile to accept the implant
    3. Epicardial adhesions or any intraoperative finding that would complicate access or closure of the atrium in which the device is intended to be implanted
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Microtech System

    Microtech System

    Device: Microtech sensor pressure

Interventions

  • DeviceMicrotech sensor pressure

    Microtech sensor implantation

06

What researchers measure

Primary outcomes

  1. Co-Primary Efficacy Endpoint

    1. Successful deployment of the intracardiac sensor. 2. Freedom from failure of the Microtech System to obtain valid intracardiac pressures by at least one method (CW/DB), in at least one timepoint up to 6 months.

    Time frame: 6 months

  2. Co-Primary Safety Endpoint

    1. Anatomic stability of the implant assessed by echocardiographic imaging through 1 month. 2. The incidence of device- or implant procedure-related adverse events through 1 month

    Time frame: 1 month

Secondary outcomes

  1. The earliest post-operative day at which "valid" pressure measurements can be made from the Microtech implant

    The earliest post-operative day at which "valid" pressure measurements can be made from the Microtech implant. A "valid" pressure measurement will be defined as a signal for which the system indicates a "fidelity score" \>0.7. Details of the fidelity score are provided in the protocol

    Time frame: 1 month

  2. Accuracy of Microtech pressure measurements in comparison to those obtained simultaneously by pulmonary artery catheter

    Accuracy of Microtech pressure measurements in comparison to those obtained simultaneously by pulmonary artery catheter (PAC; LAP from Microtech compared to PCWP from PAC, and RAP from Microtech and RAP from PAC or superior vena caval central line) at baseline and at a follow up between 3- and 6-months post implantation

    Time frame: pre procedure, 3-6 months

  3. Accuracy of Microtech pressure measurements in comparison to those obtained simultaneously by pulmonary artery catheter

    Accuracy of Microtech pressure measurements in comparison to those obtained simultaneously by pulmonary artery catheter (LAP from Microtech compared to PCWP from PAC, and RAP from Microtech and RAP from PAC or superior vena caval central line) at all follow visits from which data are available throughout the 1 year follow up period

    Time frame: 1 year

  4. Anatomic stability of the implant over the observation period

    Anatomic stability of the implant over the observation period, assessed by echocardiographic imaging at post-op, 1, 3-6, 9, 12 months follow-up visits

    Time frame: post operation, 1 month, 3-6 months, 9 months, 12 months

  5. The incidence of device-related adverse events

    The incidence of device-related adverse events through 1 year follow-up

    Time frame: 12 months

  6. Correlation of changes of sensor-measured atrial pressure

    Correlation of changes of sensor-measured atrial pressure with the following clinical parameters performed on the 1, 3-6, 9 and 12 month follow up visits: 1. changes of NTproBNP 2. changes of KCCQ 3. episodes of heart failure exacerbations 4. LVAD suction events 5. clinical assessments consistent with hypovolemia 6. changes in pressure measurements during RPM ramp tests

    Time frame: 1 month, 3-6 months , 9months and 12 month

  7. Usability of the system

    Usability of the system in order to obtain pressure measurements (Human Factors testing) at baseline, 3-6 months and 12 months visits

    Time frame: baseline, 30-6 months, 12 months

07

Study locations

2 sites
  • Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH
    New York, New York 10032, United States
  • Rabin Medical Center
    Petach Tikvah, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 23 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 12, 2024
StartActual
Dec 15, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06682910
Lead sponsor
Microtech Medical Technologies, Ltd
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Dec 15, 2024
Primary completion
Nov 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion